Últimas noticias sobre Emerald Holding (NYSE:EEX) Bolsa

EMERALD HOLDING INC

Emerald Holding

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.

Movimiento de acciones

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHL

ASYS

EFXT

GNFT

HYFM

LFVN

MTUS

RSLS

RVSB

STSS

SUNE

VEEE

VERO

WHLR

ReShape Lifesciences firma acuerdo exclusivo con Motion Informatics y dispara sus acciones antes de la apertura de mercado.

Acciones de ReShape Lifesciences (RSLS) se disparan un 82%; Aquí están 20 acciones que se mueven en premercado

Movers_Stocks

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

RNAC

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

ADTX

APTO

CSAI

DSGN

EFOI

EWCZ

GLYC

GRAB

HEES

INLF

LVWR

MGOL

MTRX

NESR

NTIC

TNMG

Las acciones de GCL Global suben más del 100% en premercado tras su fusión. Descubre qué otras acciones están en movimiento hoy.

Acciones de GCL Global Holdings (GCL) se disparan un 107%; 20 acciones que se mueven en el premercado

Emerald Holding Inc

Emerald Holding Inc 7% PRF PERPETUAL USD - Ser A

Dario's new research shows sustained outcomes post-GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to leverage these findings in commercial discussions
NEW YORK, June 24, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) ("Dario" or the "Company"), a leader in the global digital health market, today announced four new studies presented this past weekend at the 85th Annual American Diabetes Association ("ADA") Scientific Sessions in Chicago. The research, which represents Dario's 25th published study at the ADA's Scientific Sessions over the last decade, includes groundbreaking findings in sustaining GLP-1 weight loss and artificial intelligence ("AI")-powered personalization that highlight the Company's platform's critical contribution in the digital health market.
 Key highlights from the research include a dramatic eA1c reduction from 9.0% to 6.7% in GLP-1 users, with users seeing sustained results for six (6) months after medication discontinuation, and AI predictive accuracy of 89% for future glucose levels, demonstrating Dario's unique position to deliver value in the GLP-1 market where payers and employers seek solutions that maximize their investment in these costly medications. The Company is currently leveraging these findings in ongoing implementations and commercial discussions with payers and self-insured employers seeking integrated solutions for chronic condition management, particularly around GLP-1 optimization programs. &nbsp;
Landmark GLP-1 Study Demonstrates Sustainable Results Beyond Medication
The first study examined 715 GLP-1 users and revealed significant clinical improvements for those engaging with Dario's platform. Most importantly, the research showed that users who discontinued GLP-1 medication maintained stable outcomes, reflecting no significant weight or glucose rebound, for at least six (6) months, addressing a critical industry challenge where patients typically experience rebound effects after stopping treatment.
&nbsp;Key study results included:
<ul>
<li>Among continued GLP-1 users with elevated glucose levels, average blood glucose dropped from an eA1c of 9.0% to 6.7%.</li>
<li>Digital lifestyle engagement activities significantly enhanced outcomes with meal and physical activity logging associated with stronger blood glucose improvements.
<ul>
<li>Weight logging and educational content were linked to greater weight reduction.</li>
</ul>
</li>
<li>Members who discontinued GLP-1s experienced no significant weight or glucose rebound over six (6) months, with outcomes remaining statistically equivalent to those who continued medication.</li>
</ul>
These findings underscore the importance of integrated digital tools in supporting medication adherence, optimizing outcomes, and sustaining progress even after GLP-1 treatment ends.

Biotech

General

DRIO

DarioHealth Unveils Research Showing Sustained Outcomes Post-GLP-1 For Platform Users And 89% Accuracy In Innovative AI Blood Glucose Prediction At ADA 2025

Morgan Stanley analyst Cedar Ekblom initiates coverage on Amrize (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRZ#NYSE">AMRZ</a>) with a Overweight rating and announces Price Target of $62.

Price Target

Initiation

Analyst Ratings

AMRZ

Morgan Stanley Initiates Coverage On Amrize with Overweight Rating, Announces Price Target of $62

Cantor Fitzgerald analyst Carter Gould reiterates Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral and maintains $305 price target.

Reiteration

AMGN

Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $305 Price Target

Barclays analyst Luke Sergott initiates coverage on Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) with a Equal-Weight rating and announces Price Target of $300.

MEDP

Barclays Initiates Coverage On Medpace Hldgs with Equal-Weight Rating, Announces Price Target of $300

Icon Energy Corp. ("Icon" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>), an international shipping company providing worldwide seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels, is pleased to announce the successful delivery of the M/V Charlie to its fleet.
Delivery. On June 21, 2025, Icon took delivery of the M/V Charlie, a 2020-built, scrubber-fitted, eco Ultramax dry bulk carrier, it had agreed to bareboat charter-in from an unaffiliated third party, as previously announced on March 24, 2025.
Charter. The M/V Charlie has been time chartered-out to a reputable dry bulk operator for a period of 9 to 12 months, at a floating daily hire rate linked to the Baltic Supramax Index. In addition to the daily hire rate, Icon will also receive a share of the fuel cost savings to be realized by the charterer through the use of the vessel's scrubber. The time charter commenced immediately upon delivery of the M/V Charlie to Icon.

ICON

Icon Energy Adds Scrubber-Fitted M/V Charlie To Fleet, Secures 9-12 Month Time Charter; Icon Will Also Receive A Share Of The Fuel Cost Savings To Be Realized By The Charterer Through The Use Of The Vessel's Scrubber

Cantor Fitzgerald analyst Derek Soderberg reiterates SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) with a Overweight and maintains $2 price target.

Cantor Fitzgerald Reiterates Overweight on SES AI, Maintains $2 Price Target

Management

WRAP

Wrap Technologies Appoints Gerald "Jerry" Ratigan as CFO

Compass Point analyst Ed Engel initiates coverage on Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) with a Neutral rating and announces Price Target of $205.

CRCL

Compass Point Initiates Coverage On Circle Internet Group with Neutral Rating, Announces Price Target of $205

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.70</td>
<td align="right">2.30</td>
<td align="right">1.07</td>
<td>2.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">245.43</td>
<td align="right">2.55</td>
<td align="right">1.04</td>
<td>73.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.26</td>
<td align="right">0.44</td>
<td align="right">0.86</td>
<td>219.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">104.75</td>
<td align="right">0.86</td>
<td align="right">0.82</td>
<td>2.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">144.52</td>
<td align="right">0.66</td>
<td align="right">0.45</td>
<td>9.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.23</td>
<td align="right">0.17</td>
<td align="right">0.40</td>
<td>2.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">132.66</td>
<td align="right">0.50</td>
<td align="right">0.37</td>
<td>13.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.67</td>
<td align="right">0.27</td>
<td align="right">0.33</td>
<td>2.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.42</td>
<td align="right">0.18</td>
<td align="right">0.22</td>
<td>14.2K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.25</td>
<td align="right">-0.78</td>
<td align="right">-0.91</td>
<td>436.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 24, 2025

ENVB

Enveric Biosciences Announces Additional Data Indicating EB-003 Acts As An Agonist Of Serotonin Receptor 5-HT1B

PSTG

Pure Storage Appoints Tarek Robbiati As CFO, Succeeding Kevan Krysler, Effective Immediately

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million shares of its common stock (Common Stock) to a select group of accredited investors in a registered direct offering (the Offering), at a price per share of $4.67. The Offering is expected to close on June 25, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting offering-related expenses payable by the Company.
The investors in the Offering include existing healthcare-focused institutional investors, executive officers, and members of the Company's Board of Directors.

Offerings

CADL

Candel Therapeutics Announces $15M Registered Direct Offering Of 3.2M Shares At $4.67 Per Share

Deutsche Bank analyst Matthew Niknam maintains CommScope Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) with a Hold and raises the price target from $6 to $7.5.

COMM

Deutsche Bank Maintains Hold on CommScope Holding Co, Raises Price Target to $7.5

22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), the only tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced major updates to its Pinnacle product manufacturing and marketing agreement with its top-5 c-store chain customer, including the launch of four new Pinnacle SKUs, including two in the low nicotine product category. The agreement includes a merchandising agreement to potentially expand the availability of Pinnacle products to include other retail and c-store chains.
The new agreement includes two partner VLN products, Pinnacle VLN&#xAE; Gold cigarettes and Pinnacle Menthol VLN&#xAE; cigarettes which will be sold at approximately 1,700 stores across 27 states. Sales to customers are expected to begin in late summer and early fall of 2025, with stocking orders in advance, as state approvals are secured.

XXII

22nd Century Announces Updates To Pinnacle Product Manufacturing And Marketing Agreement With Top-5 C-Store Chain Customer; Launches Pinnacle VLN And Moist Snuff Products In More Than 1,700 Stores Across 27 States

<a href="https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm" title="https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm">https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm</a>

Guidance

Schlumberger N.V. Says Looking Broadly Across Energy Markets, There Has Been A Lot Of Uncertainty This Quarter; Commitment To Returning A Minimum Of $4B To Shareholders In 2025 Is Unchanged

Cantor Fitzgerald analyst Matthew Prisco maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Overweight and raises the price target from $90 to $105.

Cantor Fitzgerald Maintains Overweight on Teradyne, Raises Price Target to $105

Homeowners have on average, $181,000 in equity. This new product helps them access it before transitioning to a new home
DETROIT, June 24, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455287-1&amp;h=3636688888&amp;u=https%3A%2F%2Frocket.com%2Fmortgage%2F&amp;a=Rocket+Mortgage">Rocket Mortgage</a>, the nation's largest mortgage lender and a part of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455287-1&amp;h=1515700121&amp;u=https%3A%2F%2Fwww.rocketcompanies.com%2F&amp;a=Rocket+Companies">Rocket Companies</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), today announced the launch of bridge loans – a strategic solution designed to help buyers wrestle back control in today's competitive housing market. This new product allows current homeowners to use equity to compete shoulder-to-shoulder with cash buyers – allowing them to purchase their next primary residence before selling their current one. This provides both financial flexibility and eliminates the uncertainty and reluctance of home sellers that often comes with so-called 'contingent' offers.
With high home prices and tight housing inventory, many buyers struggle to compete without first selling – leading to delays and missed opportunities. Yet the average homeowner has $181,000 in untapped equity, a powerful resource to make a strong offer.¹ &nbsp;Rocket Mortgage's bridge loan unlocks that equity upfront, providing funds for a down payment or closing costs in the interim.

Rocket Mortgage Launches Bridge Loans To Help Homeowners Access Equity And Compete With Cash Buyers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs lowered Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) price target from $48 to $46. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. Advance Auto Parts shares closed at $51.93 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/AAP/analyst-ratings">view this stock</a>.</li>
<li>Guggenheim increased the price target for Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from $50 to $68. Guggenheim analyst Seamus Fernandez maintained a Buy rating. Cidara Therapeutics shares closed at $44.95 on Monday. <a href="https://www.benzinga.com/quote/CDTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) price target from $15 to $20. Needham analyst Serge Belanger maintained a Buy rating. CorMedix shares closed at $16.56 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/CRMD/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Lyell Immunopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) from $1 to $10. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Neutral rating. Lyell Immunopharma shares closed at $8.99 on Monday. <a href="https://www.benzinga.com/quote/LYEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $199 to $179. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. RH shares closed at $186.22 on Monday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut DICK&#8217;S Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) price target from $250 to $240. B of A Securities analyst Robert Ohmes maintained a Buy rating. DICK&#8217;S Sporting shares settled at $175.79 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised MACOM Technology Solutions Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) price target from $250 to $270. B of A Securities analyst Vivek Arya maintained a Buy rating. MACOM Technology Solutions shares closed at $138.65 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc increased Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) price target from $220 to $240. Keybanc analyst Steve Barger maintained an Overweight rating. Westinghouse Air Brake Technologies shares closed at $202.19 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from $200 to $220. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Applied Materials shares settled at $171.96 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald increased Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) price target from $90 to $115. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Lam Research shares closed at $91.61 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png" alt="" class="wp-image-959828" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

AMAT

CDTX

CRMD

CTVA

LRCX

LYEL

MTSI

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Cantor Fitzgerald analyst Matthew Prisco maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Neutral and lowers the price target from $110 to $90.

ONTO

Cantor Fitzgerald Maintains Neutral on Onto Innovation, Lowers Price Target to $90

Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis
No new safety signals observed
SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN&#xAE;&nbsp;(valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, D.C., June 21-25, 2025.
The Phase 3 GENEr8-1 trial demonstrated that durable bleed control and sustained factor VIII (FVIII) expression were maintained five years after treatment with ROCTAVIAN. FVIII activity remained consistent with previously reported results, and no new safety signals were observed. Across the entire trial, no participants developed FVIII inhibitors or experienced thromboembolic events, and there were no treatment-related malignancies across the five years of the study.

BMRN

BioMarin Pharma Presents New Data Underscoring Long-Term Efficacy And Safety Of ROCTAVIAN At Congress Of ISTH

Press Releases

Emerald Completes Refinancing and Upsizing of $515 Million Term Loan and Revolver Extension

Emerald Announces Date for Fourth Quarter and Full Year 2024 Financial Results Conference Call; Declares Quarterly Dividend

Emerald Reports Fourth Quarter and Full Year 2024 Financial Results

Emerald Agrees to Acquire Global Portfolio of Experiential and Luxury Travel Industry B2B Events

Emerald Acquires Insurtech Insights, a Global Leader in Insurance Technology Conferences and Innovation Programs

Emerald Holding, Inc. Appoints Erica Bartsch as Executive Vice President, Strategy and Communications

Comments

Emerald Holding

Noticias

Últimas noticias sobre Emerald Holding (NYSE:EEX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL